SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
SCHEDULE
13G
(Rule
13d-102)
INFORMATION
TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO
RULES
13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO
13d-2
|
Transdel
Pharmaceuticals, Inc.
|
|
(Name
of Issuer)
|
|
Common
Stock, par value $0.001 per share
|
|
(Title
of Class of Securities)
|
|
89363T
20 9
|
|
(CUSIP
Number)
|
|
December
31, 2007
|
|
(Date
of Event Which Requires Filing of this
Statement)
|
Check
the
appropriate box to designate the rule pursuant to which this Schedule is
filed:
| o |
Rule
13d-1(b)
|
| o |
Rule
13d-1(c)
|
| x |
Rule
13d-1(d)
|
*
The
remainder of this cover page shall be filled out for a reporting person’s
initial filing on this form with respect to the subject class of securities,
and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The
information required in the remainder of this cover page shall not be deemed
to
be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934
(“Act”) or otherwise subject to the liabilities of that section of the Act but
shall be subject to all other provisions of the Act (however, see
the
Notes).
|
CUSIP
No. 89363T
20 9
|
13G
|
Page
2 of 5
Pages
|
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
1
|
NAMES
OF REPORTING PERSONS
|
|
|
|||
|
|
|
Juliet
Singh, Ph.D.
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|||
|
2
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a)
|
o
|
|||
|
|
|
|
(b)
|
o
|
||
|
|
|
|
|
|||
|
|
|
|
|
|||
|
3
|
SEC
USE ONLY
|
|
|
|||
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|||
|
4
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
|
|
|
|||
|
|
|
United
States
|
|
|
||
|
|
|
|
||||
|
|
|
|
||||
|
NUMBER
OF
|
5
|
SOLE
VOTING POWER
|
||||
|
SHARES
|
|
|
|
|||
|
BENEFICIALLY
|
|
1,953,125
|
|
|||
|
OWNED
BY
|
|
|
|
|||
|
EACH
|
|
|
|
|||
|
REPORTING
|
6
|
SHARED
VOTING POWER
|
||||
|
PERSON
WITH
|
|
|
|
|||
|
|
-
0
-
|
|||||
|
|
|
|
|
|||
|
|
|
|
||||
|
|
7
|
SOLE
DISPOSITIVE POWER
|
||||
|
|
|
|
||||
|
|
|
1,953,125
|
||||
|
|
|
|
||||
|
|
8
|
SHARED
DISPOSITIVE POWER
|
||||
|
|
|
|
||||
|
|
|
-
0
-
|
||||
|
|
|
|
||||
|
|
|
|
|
|
||
|
9
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON
|
|
|
|||
|
|
|
1,953,125
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|||
|
10
|
CHECK IF
THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
|
|
|
|||
|
|
CERTAIN
SHARES
|
|
o
|
|||
|
|
|
|
|
|
||
|
|
|
|
|
|||
|
11
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW 9
|
|
|
|||
|
|
|
|
|
|
||
|
|
|
14.2%
(1)
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|||
|
12
|
TYPE
OF REPORTING PERSON
|
|
|
|||
|
|
|
|
|
|
||
|
|
|
IN
|
|
|
||
|
|
|
|
|
|
||
|
(1)
|
Based
upon an aggregate of 13,727,004 shares of common stock outstanding
as of
February 5, 2008, based upon the Issuer’s Registration Statement on Form
SB-2, dated February 7, 2008.
|
|
CUSIP
No. 89363T
20 9
|
13G
|
Page
3 of
5
Pages
|
|
Item
1.
|
|||
|
(a)
|
Name
of Issuer:
|
||
|
Transdel
Pharmaceuticals, Inc.
|
|||
|
(b)
|
Address
of Issuer's Principal Executive Offices:
|
||
|
4225
Executive Square, Suite 460
|
|||
|
La
Jolla, California 92037
|
|||
| Item 2. | |||
|
(a)
|
Name
of Person Filing:
|
||
| Juliet Singh, Ph.D. | |||
|
(b)
|
Address
of Principal Business Office, or if none, Residence:
|
||
| 4225 Executive Square, Suite 460 | |||
| La Jolla, California 92037 | |||
|
(c)
|
Citizenship:
|
||
| United States | |||
|
(d)
|
Title
of Class of Securities:
|
||
| Common Stock, par value $0.001 per share | |||
|
(e)
|
CUSIP
Number:
|
||
| 89363T 20 9 | |||
|
Item
3.
|
If
this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b)
or (c),
check whether
|
||
| the person filing is a: | |||
|
(a)
|
o
|
Broker
or dealer registered under Section 15 of the Act.
|
|
|
(b)
|
o
|
Bank
as defined in section 3(a)(6) of the Act.
|
|
|
(c)
|
o
|
Insurance
company as defined in section 3(a)(19) of the Act.
|
|
|
(d)
|
o
|
Investment
company registered under section 8 of the Investment Company Act
of
|
|
|
|
1940.
|
||
|
(e)
|
o
|
An
investment adviser in accordance with Rule
13d-1(b)(1)(ii)(E);
|
|
|
(f)
|
o
|
An
employee benefit plan or endowment fund in accordance with Rule
13d-
|
|
|
|
1(b)(1)(ii)(F).
|
||
|
(g)
|
o
|
A
parent holding company or control person in accordance with Rule
13d-
|
|
|
1(b)(1)(ii)(G).
|
|||
|
(h)
|
o
|
A
savings association as defined in Section 3(b) of the Federal Deposit
Insurance
|
|||
|
Act;
|
|||||
|
(i)
|
o
|
A
church plan that is excluded from the definition of an investment
company
under
|
|||
|
Section
3(c)(14) of the Investment Company Act.
|
|||||
|
(j)
|
o
|
Group,
in accordance with Rule
13d-1(b)(1)(ii)(J).
|
|||
|
CUSIP
No. 89363T
20 9
|
13G
|
Page 4
of
5
Pages
|
|
Item
4.
|
Ownership
|
||||
|
(a)
|
Amount
beneficially owned:
|
||||
| 1,953,125 | |||||
|
(b)
|
Percent of Class: | ||||
| 14.2% | |||||
|
(c)
|
Number of Shares as to which the Reporting Person has: | ||||
|
(i)
|
Sole
power to vote or to direct to vote: 1,953,125
|
|||
|
(ii)
|
Shared
power to vote or to direct to vote: 0
|
|||
|
(iii)
|
Sole
power to dispose or to direct the disposition of:
1,953,125
|
|||
|
(iv)
|
Shared
power to dispose or to direct the disposition of:
0
|
|||
|
Item
5.
|
Ownership
of Five Percent or Less of a Class.
|
||||
| Not Applicable. | |||||
|
Item
6.
|
Ownership
of More than Five Percent on Behalf of Another Person.
|
||||
| Not Applicable. | |||||
|
Item
7.
|
Identification
and Classification of the Subsidiary Which Acquired the Security
Being
Reported on by the Parent Holding Company.
|
||||
|
|
|||||
| Not Applicable. | |||||
|
Item
8.
|
Identification
and Classification of Members of the Group.
|
||||
| Not Applicable. | |||||
|
Item
9.
|
Notice
of Dissolution of Group.
|
||||
| Not Applicable. | |||||
|
Item
10.
|
Certification.
|
||||
| Not Applicable. | |||||
|
CUSIP
No. 89363T
20 9
|
13G
|
Page 5
of
5
Pages
|
SIGNATURES
After
reasonable inquiry and to the best of my knowledge and belief, I certify
that
the information set forth in this statement is true, complete and
correct.
|
Dated:
February 14, 2008
|
||
|
/s/
Juliet Singh, Ph.D.
|
||
|
Juliet
Singh, Ph.D.
|